Patents by Inventor Mark Eiteman

Mark Eiteman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Microbial production of pyruvate and other metabolites
    Publication number: 20050255572
    Abstract: Microbial production of pyruvate and metabolites derived from pyruvate in cells exhibiting reduced pyruvate dehydrogenase activity compared to wild-type cells. Acetate and glucose are supplied as a carbon sources.
    Type: Application
    Filed: August 20, 2004
    Publication date: November 17, 2005
    Applicant: University of Georgia Research Foundation, Inc.
    Inventors: Mark Eiteman, Elliot Altman
  • Metabolically engineered organisms for enhanced production of oxaloacetate-derived biochemicals
    Publication number: 20030087381
    Abstract: Metabolic engineering is used to increase the carbon flow toward oxaloacetate to enhance production of bulk biochemicals, such as lysine and succinate, in industrial fermentations. Carbon flow is redirected by genetically engineering the cells to overexpress the enzyme pyruvate carboxylase.
    Type: Application
    Filed: August 9, 2002
    Publication date: May 8, 2003
    Applicant: University of Georgia Research Foundation, Inc.
    Inventors: Ravi R. Gokarn, Mark A. Eiteman, Elliot Altman
  • Metabolically engineered E. coli for enhanced production of oxaloacetate-derived biochemicals
    Patent number: 6455284
    Abstract: Metabolic engineering is used to increase the carbon flow toward oxaloacetate to enhance production of bulk biochemicals, such as lysine and succinate, in bacterial fermentations. Carbon flow is redirected by genetically engineering the cells to overexpress the enzyme pyruvate carboxylase.
    Type: Grant
    Filed: October 13, 1999
    Date of Patent: September 24, 2002
    Assignee: The University of Georgia Research Foundation, Inc.
    Inventors: Ravi R. Gokarn, Mark A. Eiteman, Elliot Altman